title: Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
authors: From the School for Mental Health and Neuroscience (L.R., A.-H.M., R.H.) and the Central Diagnostic Laboratory (J.D.), Maastricht University Medical Center; and Academic MS Center Limburg (L.R., A.-H.M., R.H.) and the Department of Cardiology, Orbis Medical Center (M.v.D.), Sittard, the Netherlands.
authors: Linda
authors: L
authors: Rolf
authors: Anne-Hilde
authors: AH
authors: Muris
authors: Jan
authors: J
authors: Damoiseaux
authors: Marc
authors: M
authors: van Daele
authors: Raymond
authors: R
authors: Hupperts
mesh_terms: D000328:Adult; D001281:Atrial Fibrillation / Q000139:chemically induced*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy; D011409:Propylene Glycols / Q000009:adverse effects*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine